Efficacy of additional combination therapy with brentuximab vedotin
Higher survival rate and less secondary cancer compared to standard therapies
In the treatment of advanced Hodgkin’s lymphoma, a rare disease, a study has found that targeted therapies are more effective than standard therapies to increase the survival rate.
National Cancer Center Hematology Cancer Center Professor Uhm Hyun-seok (hematologic oncologist) said that the standard therapy ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and the targeted therapy brentuximab vedotin A+AVD (Bren) The effects of tuximab vedotin + doxorubicin, vinblastine, and dacarbazine) were compared and published in NEJM.
Hodgkin’s lymphoma, a blood cancer, is a rare disease that occurs in regarding 300 people annually in Korea. Until now, ABVD has been used as the standard therapy, but there is a limit to increasing the survival rate.
The subjects of this study were 1,334 adult patients with stage 3 or 4 advanced Hodgkin’s lymphoma who had no treatment experience. They were divided into the standard therapy group (670 patients) and the concomitant therapy group (664 patients), and overall survival (OS), progression-free survival (PFS), and secondary cancer incidence were compared.
As a result, the 6-year overall survival (OS) was superior in the combination therapy group (89.4% vs. 93.9%). The progression-free survival rate was also long and the incidence of secondary cancer was low (32 vs. 23).
© Medical Tribune Unauthorized reproduction and redistribution prohibited
